BioVie's patented Orphan drug candidate, BIV201, could improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, NASH, etc. it's about to start a US Phase 2a trial in a common complication, ascites, which is a serious unmet medical need as the FDA has never approved a drug to treat this condition. The active agent in BIV201 therapy is approved in ~40 countries but not the US.